Drugs / Pirmitegravir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05869643 | May 2023 → Apr 2026 | HIV infectious disease | ST Pharm Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-02-23 | ST Pharm Co., Ltd. | Results [안내] Pirmitegravir (STP0404)의 X-선 결정구조와 이에 따른 기전연구에 대한 논문 국제 저널 게재 stpharm.co.kr ↗
Our results explain the mechanism of the ALLINI-induced condensation of HIV-1 IN and provide a reliable template for the rational development of this series of antiretrovirals through the optimization of their key contacts with the viral target. |
| 2022-08-30 | ST Pharm Co., Ltd. | Regulatory 에스티팜, ALLINI HIV 감염증 미국 임상2a상 IND 신청 stpharm.co.kr ↗ |
| 2021-07-23 | ST Pharm Co., Ltd. | Results 에스티팜, 에이즈치료제 STP0404 전임상 결과 국제학술지 논문 게재 stpharm.co.kr ↗ |
All press releases naming this drug 13 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pirmitegravir | “Low-dose STP0404 (Pirmitegravir)” NCT05869643 ↗ |
| Known as | STP0404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05869643 ↗ |
| Modality | Small molecule | — CHEMBL5095077 ↗ |
| Route | Oral | “Once daily, oral capsule taken after breakfast” NCT05869643 ↗ |